IL106520A - FLUORINATED 17b-SUBSTITUTED 4-AZA-5a- ANDROSTANE- 3-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

FLUORINATED 17b-SUBSTITUTED 4-AZA-5a- ANDROSTANE- 3-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
IL106520A
IL106520A IL106520A IL10652093A IL106520A IL 106520 A IL106520 A IL 106520A IL 106520 A IL106520 A IL 106520A IL 10652093 A IL10652093 A IL 10652093A IL 106520 A IL106520 A IL 106520A
Authority
IL
Israel
Prior art keywords
hydrogen
fluorine
alkyl
androstane
aza
Prior art date
Application number
IL106520A
Other languages
English (en)
Other versions
IL106520A0 (en
Inventor
Achille Panzeri
Marcella Nesi
Enrico Di Salle
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of IL106520A0 publication Critical patent/IL106520A0/xx
Publication of IL106520A publication Critical patent/IL106520A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL106520A 1992-07-31 1993-07-29 FLUORINATED 17b-SUBSTITUTED 4-AZA-5a- ANDROSTANE- 3-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IL106520A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929216284A GB9216284D0 (en) 1992-07-31 1992-07-31 Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives

Publications (2)

Publication Number Publication Date
IL106520A0 IL106520A0 (en) 1993-11-15
IL106520A true IL106520A (en) 1997-11-20

Family

ID=10719598

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106520A IL106520A (en) 1992-07-31 1993-07-29 FLUORINATED 17b-SUBSTITUTED 4-AZA-5a- ANDROSTANE- 3-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (29)

Country Link
US (1) US5407939A (hu)
EP (1) EP0607400B1 (hu)
JP (1) JP3325025B2 (hu)
KR (1) KR100311547B1 (hu)
CN (1) CN1041096C (hu)
AT (1) ATE159951T1 (hu)
AU (1) AU660562B2 (hu)
CA (1) CA2120343A1 (hu)
CZ (1) CZ286240B6 (hu)
DE (1) DE69315050T2 (hu)
DK (1) DK0607400T3 (hu)
ES (1) ES2110620T3 (hu)
FI (1) FI113778B (hu)
GB (1) GB9216284D0 (hu)
GR (1) GR3025546T3 (hu)
HK (1) HK1011693A1 (hu)
HU (2) HUT67043A (hu)
IL (1) IL106520A (hu)
MX (1) MX9304579A (hu)
MY (1) MY109633A (hu)
NO (1) NO305401B1 (hu)
NZ (1) NZ254787A (hu)
PH (1) PH29938A (hu)
PL (1) PL178591B1 (hu)
RU (1) RU2125061C1 (hu)
TW (1) TW286319B (hu)
UA (1) UA41291C2 (hu)
WO (1) WO1994003475A1 (hu)
ZA (1) ZA935481B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220064B (hu) * 1992-12-18 2001-10-28 Merck And Co. Inc. Eljárás 17béta-(N-monoszubsztituált-karbamoil)-4-aza-5alfa-androszt-1-én-3-ont tartalmazó krónikus prosztatitisz kezelésére alkalmas gyógyászati készítmény előállítására
AU681585B2 (en) * 1993-06-24 1997-09-04 Richter Gedeon Vegyeszeti Gyar Rt. Novel process for preparing 17beta -substituted 4-azaandrostane derivatives
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
KR100363994B1 (ko) * 1993-10-21 2003-04-10 머크 앤드 캄파니 인코포레이티드 16-치환된-4-아자-안드로스탄5-알파-리덕타제아이소자임1억제제
GB9415178D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 4-azasteroids with side-chain fluoroketones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
IT1275594B1 (it) * 1995-07-21 1997-08-06 Pharmacia S P A Ora Pharmacia Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5alfa-androst-1-ene-17beta-carbossammide
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
GB9727522D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Process for preparing carboxamido-4-azasteroids
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
RU2320670C2 (ru) * 2002-03-13 2008-03-27 Мерк Энд Ко., Инк. Фторированные производные 4-азастероида в качестве модуляторов рецептора андрогена
CA2530182A1 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521297A (ja) * 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
CN1816370A (zh) * 2003-06-30 2006-08-09 麦克公司 用作雄激素受体调节剂的17－乙酰氨基－4－氮杂甾族化合物衍生物
AU2004259664B2 (en) * 2003-06-30 2009-05-28 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
CN1849126A (zh) 2003-09-10 2006-10-18 默克公司 作为雄激素受体调节剂的17－杂环－4－氮杂甾族衍生物
JP2007505120A (ja) * 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
US20080125399A1 (en) * 2004-04-08 2008-05-29 Jiabing Wang 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
AU2009320250A1 (en) * 2008-10-28 2010-06-03 Biomarin Pharmaceutical Inc. Decahydro-1H-indenoquinolinone and decahydro-3H-cyclopentaphenanthridinone CYP17 inhibitors
KR102541494B1 (ko) 2019-09-11 2023-06-08 주식회사 엘지화학 고흡수성 수지의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
GB9002922D0 (en) * 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
AUPP930799A0 (en) * 1999-03-18 1999-04-15 University Of Sydney, The Optical planar waveguide device and method of its fabrication

Also Published As

Publication number Publication date
KR100311547B1 (ko) 2002-06-20
FI941424A (fi) 1994-05-27
JPH06511497A (ja) 1994-12-22
CZ286240B6 (cs) 2000-02-16
ATE159951T1 (de) 1997-11-15
NO941080D0 (no) 1994-03-24
MX9304579A (es) 1994-02-28
AU660562B2 (en) 1995-06-29
CN1041096C (zh) 1998-12-09
GR3025546T3 (en) 1998-03-31
MY109633A (en) 1997-03-31
UA41291C2 (uk) 2001-09-17
FI941424A0 (fi) 1994-03-28
NO305401B1 (no) 1999-05-25
IL106520A0 (en) 1993-11-15
US5407939A (en) 1995-04-18
PH29938A (en) 1996-09-16
DK0607400T3 (da) 1998-01-26
HK1011693A1 (en) 1999-07-16
ZA935481B (en) 1994-05-16
AU4704893A (en) 1994-03-03
DE69315050D1 (de) 1997-12-11
HU211238A9 (en) 1995-11-28
RU2125061C1 (ru) 1999-01-20
PL178591B1 (pl) 2000-05-31
CZ153893A3 (en) 1994-02-16
WO1994003475A1 (en) 1994-02-17
DE69315050T2 (de) 1998-03-05
NZ254787A (en) 1995-11-27
CN1085224A (zh) 1994-04-13
CA2120343A1 (en) 1994-02-17
NO941080L (no) 1994-05-18
TW286319B (hu) 1996-09-21
FI113778B (fi) 2004-06-15
ES2110620T3 (es) 1998-02-16
HU9400914D0 (en) 1994-06-28
EP0607400A1 (en) 1994-07-27
HUT67043A (en) 1995-01-30
GB9216284D0 (en) 1992-09-16
EP0607400B1 (en) 1997-11-05
JP3325025B2 (ja) 2002-09-17

Similar Documents

Publication Publication Date Title
IL106520A0 (en) Fluorinated 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives,their preparation and pharmaceutical compositions containing them
NO950849D0 (no) Derivater av valproin og 2-valproensyreamider og anvendelse som antikonvulsanter
DK0490566T3 (da) Fremstilling og anvendelse af N-iodpropargyloxycarbonylaminosyreestere og derivater som antimikrobielle midler
ATE83773T1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
ES8303395A1 (es) "procedimiento de preparar compuestos benzoxepinicos y analogos".
IE821434L (en) Arylsulphonamides.
NO941461L (no) 3-deoksy-oligosakkarider, fremgangsmåter for fremstilling derav og farmasöytiske blandinger inneholdende dem
HU9503090D0 (en) Novel bisoxadiazolidine derivative
IL99244A0 (en) Penem compounds
IL75887A0 (en) Indoloindole derivatives,their preparation and pharmaceutical compositions containing them
ES8201539A1 (es) Procedimiento de preparacion de nuevas ortoarilideneaminofe-netilaminas y de sus sales de adicion con acidos farmacolo- gicamente compatibles
IL106564A (en) Tetrahydronaphthalene derivatives their preparation and pharmaceutical compositions containing them
SG47940A1 (en) Light screening agent
ES8800663A1 (es) Procedimiento para preparar compuestos arilsulfonicos.
IL84266A (en) 1-hydroxyalkyl-3-alkylxanthines and pharmaceutical compositions containing them
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
RH Patent void
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees